“Cost-effectiveness analysis of paclitaxel + carboplatin vs. alternative combinations in the treatment of non-small cell lung cancer”, FE, vol. 7, no. 2, pp. 97–117, Sep. 2006, doi: 10.7175/fe.v7i2.680.